Keryx Biopharmaceuticals Given New $30.00 Price Target at Mizuho (KERX)
Analysts at Mizuho decreased their target price on shares of Keryx Biopharmaceuticals (NASDAQ:KERX) from $32.00 to $30.00 in a research report issued to clients and investors on Friday. Mizuho’s target price would suggest a potential upside of 90.84% from the stock’s previous close.
KERX has been the subject of a number of other recent research reports. Analysts at HC Wainwright reiterated a “buy” rating on shares of Keryx Biopharmaceuticals in a research note on Friday, May 23rd. They now have a $19.00 price target on the stock. Analysts at MLV & Co
cut their price target on shares of Keryx Biopharmaceuticals from $27.00 to $21.00 in a research note on Monday, May 12th. They now have a “buy” rating on the stock. Eight research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $23.89.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded down 0.44% on Friday, hitting $15.73. The stock had a trading volume of 1,284,682 shares. Keryx Biopharmaceuticals has a 52 week low of $8.29 and a 52 week high of $17.46. The stock has a 50-day moving average of $15.10 and a 200-day moving average of $14.83. The company’s market cap is $1.439 billion.
Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Thursday, August 7th. The company reported ($0.24) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.25) by $0.01. During the same quarter in the prior year, the company posted ($0.14) earnings per share. Analysts expect that Keryx Biopharmaceuticals will post $-0.81 EPS for the current fiscal year.
Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.